Abivax Launches $600M Public Offering of ADSs to Fund Drug Commercialization
ABVX has more than doubled off its 52-week low of $7.41 on elevated volume (4.6× avg).
Summary
Abivax has launched an underwritten public offering of approximately $600 million in American Depositary Shares (ADSs). This significant capital raise follows shareholder approval in May for such programs and comes on the heels of highly positive Phase 3 results for its lead drug candidate, obefazimod. While dilutive for existing shareholders, the offering provides substantial funding for the potential commercialization of obefazimod in the U.S. and further clinical development. The final pricing and number of ADSs will be determined after a book-building process.
At the time of this announcement, ABVX was trading at $132.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $7.41 to $148.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.